Japan has something no other country on earth can replicate: a single-payer universal healthcare system covering 126 million people, with decades of structured clinical data flowing through a standardized national infrastructure. While the US fragments patient records across thousands of private insurers and the EU struggles to harmonize 27 different health data regimes, Japan sits on one of the world’s most comprehensive — and most underutilized — medical datasets. For global pharmaceutical companies, medtech startups, and health AI developers, Japan’s medical big data represents a once-in-a-generation opportunity. Here is why, how it works, and what it means for international businesses.
The Regulatory Landscape: Japan vs. the World
Medical data regulation varies dramatically across major markets. Understanding these differences is essential for any company looking to leverage health data across borders.
Japan: APPI and the Next-Generation Medical Infrastructure Act
Japan’s approach to medical data is governed by two key frameworks. The Personal Information Protection Commission (PPC) oversees the Act on the Protection of Personal Information (APPI), amended in 2022, which sets baseline rules for all personal data including medical records. On top of this, the Next-Generation Medical Infrastructure Act (NKI Act), enacted in 2018, created a specific framework for anonymizing and utilizing medical big data for research and development.
The NKI Act is Japan’s secret weapon. It established a system of government-certified “Certified Anonymized Medical Data Utilization Businesses” — organizations authorized to collect, anonymize, and provide medical data to researchers, pharmaceutical companies, and AI developers. Unlike most countries where patients must actively opt in to data sharing, the NKI Act operates on an opt-out basis: patient data flows into the system by default unless individuals explicitly refuse. This single design choice gives Japan access to a far larger and more representative dataset than opt-in systems can ever achieve.
United States: HIPAA and Fragmentation
The US relies on HIPAA (Health Insurance Portability and Accountability Act, 1996) as its primary medical data framework. HIPAA protects patient privacy but does not create any unified mechanism for aggregating or utilizing health data at scale. The result is extreme fragmentation:
- Over 900 private health insurers, each with proprietary data formats
- Thousands of independent hospital systems with incompatible EHR (Electronic Health Record) platforms
- No single national patient identifier — unlike Japan’s My Number system
- State-level privacy laws (e.g., California’s CCPA/CPRA) adding further complexity
While the US produces enormous volumes of health data, combining it into usable datasets for research or AI training requires navigating a labyrinth of legal, technical, and organizational barriers.
European Union: GDPR and the European Health Data Space
The EU’s GDPR treats health data as a “special category” requiring explicit consent for processing. This creates a high privacy bar but severely limits the volume of data available for secondary use (research, AI development). The proposed European Health Data Space (EHDS), expected to be fully operational by 2028-2029, aims to create a cross-border framework for health data sharing — but harmonizing 27 member states’ health systems is a generational project.
United Kingdom: NHS — The Gold Standard That Inspired the World
The UK’s NHS (National Health Service) is often cited as the global benchmark for medical data infrastructure. With a single-payer system covering 67 million people, the NHS has built powerful datasets including the Hospital Episode Statistics (HES) database, Clinical Practice Research Datalink (CPRD), and NHS Spine — a central patient record system linking GPs, hospitals, and pharmacies.
The UK also pioneered genomic medicine at scale through Genomics England, sequencing 100,000 genomes linked to clinical records. The UK Biobank (500,000 participants with genetic, lifestyle, and health data) is one of the most accessed research datasets globally.
However, the UK model has critical limitations compared to Japan:
- Population scale — 67M vs. Japan’s 126M, with Japan’s dataset nearly twice the size
- Aging depth — Japan’s 29%+ over-65 population generates far richer geriatric and long-term care data than the UK’s 19%
- Post-Brexit regulatory uncertainty — the UK’s departure from GDPR adequacy alignment creates ambiguity for cross-border data sharing
- GP gatekeeping model — NHS data is strong on primary care but historically weaker on specialist and acute care integration compared to Japan’s unified claims system
- Public trust challenges — the failed care.data program (2013-2016) and ongoing controversy around Palantir’s NHS Federated Data Platform have damaged public confidence in medical data sharing
Japan’s NKI Act opt-out framework, by contrast, has faced minimal public opposition — partly because it was designed with strict anonymization standards from the outset, and partly because Japanese culture places higher trust in institutional data stewardship.
China: Massive Scale, Limited Access
China’s health data volumes are enormous (1.4 billion people), but access is tightly controlled by the state. The Personal Information Protection Law (PIPL, 2021) and Data Security Law create significant barriers for foreign companies. Cross-border data transfer restrictions make it nearly impossible for international firms to leverage Chinese health data directly.
| Dimension | Japan | United States | EU | China |
|---|---|---|---|---|
| Population covered | 126M (universal) | 330M (fragmented) | 450M (27 systems) | 1.4B (state-controlled) |
| Primary framework | APPI + NKI Act | HIPAA + state laws | GDPR + EHDS (pending) | PIPL + DSL |
| Data sharing model | Opt-out | Opt-in / consent per use | Explicit consent | State-directed |
| National patient ID | Yes (My Number) | No | Varies by country | Yes (Resident ID) |
| Data standardization | High (SS-MIX2, HL7 FHIR) | Low (fragmented EHRs) | Medium (varies) | Medium |
| Foreign access feasibility | High (NKI framework) | Medium (costly) | Low (GDPR barriers) | Very low |
Sources: Personal Information Protection Commission Japan; U.S. Department of Health and Human Services, “HIPAA Overview”; European Commission, “European Health Data Space Proposal” (2022); Cyberspace Administration of China, PIPL text (2021).
What Makes Japan’s Medical Data Unique
Japan’s medical big data advantage isn’t just about regulation. It’s about the structural characteristics of the data itself.
Universal Coverage, One System
Japan’s National Health Insurance system, established in 1961, covers virtually the entire population. Every hospital visit, prescription, surgery, and diagnostic test generates a claims record (レセプト / reseputo) that flows through a standardized national infrastructure. This means Japan has longitudinal health data on 126 million people spanning decades — an asset no other developed democracy can match at this scale and consistency.
NDB: The National Database of Health Insurance Claims
The NDB (National Database), operated by MHLW (Ministry of Health, Labour and Welfare), contains over 18 billion claims records accumulated since 2009. It covers:
- All medical claims (outpatient, inpatient, dental, pharmacy)
- National health checkup data (特定健診 / tokutei kenshin) for 40-74 year olds
- DPC (Diagnosis Procedure Combination) data from acute care hospitals
In 2020, the NDB was linked with the Long-Term Care Insurance Database (介護DB), creating a combined dataset that tracks individuals from preventive health checkups through acute care to elderly care — the entire patient journey.
Certified Anonymized Data Operators
Under the NKI Act, three organizations have been certified as anonymized medical data operators:
- ICI (Information Center for Medical and Health) — focused on claims data aggregation from multiple insurers
- NTT Data — leveraging its IT infrastructure to process and anonymize hospital data
- Life Data Initiative (LDI) — working with academic medical centers
These operators can legally collect patient data from hospitals and insurers (on an opt-out basis), anonymize it to irreversible standards, and provide it to approved researchers and companies. This is the pipeline that makes Japan’s medical big data accessible.
The World’s Oldest Population = The World’s Richest Geriatric Dataset
Japan has the world’s highest proportion of people over 65 (29.3% in 2025). This demographic reality means Japan’s medical databases contain unparalleled depth in:
- Chronic disease management — diabetes, hypertension, cardiovascular disease at scale
- Dementia and neurodegenerative disorders — the largest real-world dataset on Alzheimer’s progression
- Polypharmacy — data on drug interactions in elderly patients taking 5+ medications
- Long-term care transitions — from independent living to assisted care to end-of-life
- Cancer registries — Japan’s national cancer registry covers all diagnosed cases since 2016
| Dataset | Records | Coverage | Key Strength |
|---|---|---|---|
| NDB (Claims Database) | 18B+ records | All insured citizens | Longitudinal treatment data |
| DPC Database | 8M+ discharges/year | 1,730+ acute hospitals | Inpatient procedure detail |
| National Cancer Registry | All cases since 2016 | Universal | Incidence, staging, outcomes |
| Long-Term Care DB | 6.8M+ recipients | All LTCI beneficiaries | Elderly care trajectories |
| Tokutei Kenshin (Health Checkup) | 30M+ annually | Ages 40-74 | Preventive health metrics |
Sources: MHLW, “NDB Open Data” (2024); National Cancer Center Japan, “Cancer Statistics in Japan” (2025); MHLW, “Long-Term Care Insurance System Overview” (2025).
The Global Opportunity: What Can Be Done With Japan’s Medical Data
For international companies, Japan’s medical big data opens several high-value use cases that are difficult or impossible to pursue in other markets.
1. Drug Development and Clinical Trial Optimization
Pharmaceutical companies can use Japan’s claims data to:
- Identify patient cohorts — find populations with specific conditions, comorbidities, and treatment histories for clinical trial recruitment
- Real-world evidence (RWE) studies — validate drug efficacy and safety using post-market data from millions of patients, accelerating regulatory submissions to PMDA and other agencies
- Comparative effectiveness research — compare treatment outcomes across drugs, devices, and protocols at population scale
- Rare disease identification — Japan’s universal coverage means even rare conditions have statistically significant sample sizes
For global pharma companies already running clinical trials in Japan, integrating NDB-derived real-world data can reduce Phase III trial costs by 20-30% and accelerate time-to-approval.
2. Health AI and Machine Learning
Japan’s structured, standardized medical data is ideal training material for health AI:
- Diagnostic AI models — train on Japan’s imaging and pathology data, then deploy globally
- Predictive models for chronic disease — Japan’s aging population data can predict disease progression patterns applicable worldwide as other countries age
- Drug interaction prediction — Japan’s polypharmacy data (elderly patients on multiple medications) is the world’s largest real-world dataset for modeling adverse drug interactions
- Care pathway optimization — use long-term care transition data to build AI that recommends optimal care escalation timing
3. Aging Society Solutions — Exportable Worldwide
Every developed country is aging. Japan is simply 15-20 years ahead. The insights derived from Japan’s medical big data on managing an aging population are directly applicable to:
- United Kingdom — NHS has the infrastructure but lacks Japan’s depth in geriatric data; collaboration between Japanese data operators and NHS trusts could accelerate UK aging care research
- Europe — Germany, Italy, and Spain are following Japan’s demographic trajectory
- South Korea — aging faster than Japan, urgently needs Japan’s data-driven care models
- China — facing a demographic cliff with its post-one-child-policy aging wave
- United States — the Baby Boomer retirement wave is straining Medicare and long-term care systems
Companies that build products and services on Japan’s geriatric data today will have a decisive first-mover advantage as the rest of the world catches up to Japan’s demographic reality.
4. Medical Device and Digital Health Validation
Japan’s regulatory environment under PMDA is increasingly aligned with FDA and EU MDR standards. Medical device companies can:
- Use Japanese real-world data to support regulatory filings in multiple jurisdictions simultaneously
- Validate digital therapeutics (DTx) using Japan’s insurance claims outcomes data
- Pilot remote monitoring solutions with Japan’s elderly population and use the results for global market entry
Barriers and How to Navigate Them
Japan’s medical data opportunity is real, but it’s not a free-for-all. International companies need to understand the access pathways.
Language and Data Formats
Japan’s medical claims data is in Japanese, using Japan-specific coding systems (e.g., standard disease codes mapped to ICD-10, but with local extensions). Working with the data requires either Japanese-speaking data scientists or partnership with a local intermediary who can translate, clean, and structure the data for international use.
NKI Certified Operator Access
Foreign companies cannot directly access anonymized data under the NKI Act. They must work through or in partnership with a certified operator (ICI, NTT Data, or LDI) or a Japanese research institution. This is not a barrier — it’s a gatekeeper that ensures data quality and compliance, while still enabling commercial use.
Ethical Review Requirements
Research using Japanese medical data requires ethical review board (IRB) approval, consistent with international standards. Companies accustomed to IRB processes in the US or EU will find Japan’s requirements familiar, though documentation must be in Japanese.
Cross-Border Data Transfer
Under APPI, cross-border transfer of personal data requires either the recipient country having “equivalent” data protection standards (the EU qualifies under its adequacy agreement with Japan) or individual consent. However, since NKI Act data is anonymized to irreversible standards, it is no longer classified as personal data — meaning it can be transferred internationally without APPI cross-border restrictions.
This is a critical point: anonymized medical big data from Japan can flow across borders freely.
The Proposal: Bridging Japan’s Data to Global Markets
The opportunity is clear. Japan has the data. The world has the need. What’s missing is the bridge.
Most international pharmaceutical companies, health AI startups, and medtech firms know Japan as a clinical trial market or a device sales target. Very few have recognized that Japan’s medical big data infrastructure — the NDB, the NKI Act framework, the certified operators — represents a globally unique asset for R&D, AI training, and aging society product development.
The companies that act on this now will:
- Build AI models on the world’s deepest geriatric dataset — and deploy them globally as populations age
- Generate real-world evidence at population scale — accelerating drug and device approvals across multiple regulatory jurisdictions
- Develop aging society solutions in Japan first — then export them to Europe, Korea, China, and the Americas as demand surges
- Establish partnerships with Japanese hospitals, insurers, and data operators — building long-term competitive moats in health data access
Japan’s window of advantage won’t last forever. As other countries build their own health data infrastructure (the EU’s EHDS, India’s ABDM), the first-mover advantage will narrow. The time to engage is now.
How Japonity Can Help
At Japonity, we specialize in connecting international businesses with Japan’s healthcare ecosystem. Our team understands both the regulatory framework and the business landscape — and we have direct relationships with the key players in Japan’s medical data infrastructure.
We can help you:
- Navigate the NKI Act framework — identify the right certified operator and data access pathway for your use case
- Connect with Japanese hospitals and research institutions — for collaborative R&D, clinical validation, and pilot programs
- Structure cross-border partnerships — ensuring compliance with APPI, PMDA, and international data standards
- Develop market entry strategy — for health AI, digital therapeutics, medical devices, and pharmaceutical products targeting Japan and beyond
Japan’s medical big data is one of the most valuable — and most accessible — health data assets in the world. If your business operates in pharmaceuticals, health AI, digital health, medical devices, or aging society solutions, we should talk.
Ready to explore Japan’s medical big data opportunity? Contact Japonity — we bridge the gap between global health innovation and Japan’s unmatched medical data infrastructure.
